Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedländer, Éric Pujade-Lauraine, Lari Wenzel et al.|The Lancet Oncology|2018Cited by 137
Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.Michael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|Journal of Clinical Oncology|2017Cited by 18
Health-related quality of life (HRQOL) and patient-centred outcomes with olaparib maintenance post-chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer (PSR SOC).Michael Friedländer, Éric Pujade-Lauraine, Val Gebski et al.|Unknown|2017Cited by 1